ZSCAN25: A Scaffold Protein with Multiple Signaling Pathways and Potential Therapeutic Applications

Target Name: ZSCAN25

NCBI ID: G221785

ZSCAN25

ZSCAN25: A Scaffold Protein with Multiple Signaling Pathways and Potential Therapeutic Applications

ZSCAN25 (ZSCAN25 variant X4) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a scaffold protein that is involved in the formation of blood vessels, and it has been shown to play a role in the development and progression of various diseases, including cancer.

One of the unique features of ZSCAN25 is its ability to interact with multiple signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. This makes it an attractive target for drug development, as it allows for the development of compounds that can modulate its activity and improve therapeutic outcomes.

ZSCAN25 has also been shown to be involved in the regulation of cellular processes that are important for brain development and function, such as the formation of new blood vessels, the regulation of neurotransmitter release, and the maintenance of cellular signaling pathways. This suggests that it may be an important biomarker for the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential clinical applications, ZSCAN25 has also generated a lot of interest among researchers due to its unique structure and biology. The ZSCAN25 protein is composed of a single chain of amino acids that is approximately 25 kDa in length. It has a characteristic topology, with a hydrophobic region at the N-terminus and a hydrophilic region in the middle.

The hydrophobic region of ZSCAN25 is rich in secondary structure elements, including a long sequence of hydrophobic amino acids (155 amino acids), a 尾-sheet, and a 尾-helix. This structural feature is unique, as it is not typically found in proteins that are involved in the formation of blood vessels. The 尾-sheet and 尾-helix are important structural elements that are involved in the regulation of protein function, and the presence of these features in ZSCAN25 suggests that it has a unique mechanism of regulation.

Furthermore, ZSCAN25 has a unique post-translational modification profile. It can be modified by various post-translational modification techniques, including phosphorylation, ubiquitination, and tyrosination. These modifications play important roles in the regulation of protein function and may be involved in the mechanisms of action of ZSCAN25.

In conclusion, ZSCAN25 is a protein that has a unique structure and biology. Its ability to interact with multiple signaling pathways and its involvement in the regulation of cellular processes important for brain development and function make it an attractive target for drug development. Furthermore, its unique post-translational modification profile and its ability to form blood vessels make it a promising biomarker for the development and progression of neurodegenerative diseases.

It is important to note that this article is for informational purposes only and should not be considered medical advice. Further research is needed to determine the exact role of ZSCAN25 in disease progression and to develop effective treatments.

Protein Name: Zinc Finger And SCAN Domain Containing 25

Functions: May be involved in transcriptional regulation

The "ZSCAN25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZSCAN25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets